| Schedule of segment reporting |
| Schedule
of segment reporting |
|
|
|
|
|
|
|
|
| |
|
For the
Six Months Ended
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
| Revenues |
|
$ |
39,990 |
|
|
$ |
63,000 |
|
| |
|
|
|
|
|
|
|
|
| Less: Significant and other segment expenses: |
|
|
|
|
|
|
|
|
| NEO100 |
|
|
688,628 |
|
|
|
456,721 |
|
| NEO100-02 |
|
|
201,787 |
|
|
|
123,431 |
|
| NEO212 |
|
|
455,629 |
|
|
|
359,696 |
|
| Pediatric |
|
|
99,010 |
|
|
|
68,988 |
|
| Laboratory |
|
|
192,377 |
|
|
|
- |
|
| Other |
|
|
38,123 |
|
|
|
165 |
|
| Total research and development expense |
|
|
1,675,554 |
|
|
|
1,009,001 |
|
| |
|
|
|
|
|
|
|
|
| Advisory fee |
|
|
11,737,806 |
|
|
|
- |
|
| Legal and accounting |
|
|
1,477,909 |
|
|
|
1,155,338 |
|
| Employee Expenses |
|
|
334,160 |
|
|
|
145,724 |
|
| Debt issuance and deferred offering costs amortization |
|
|
360,200 |
|
|
|
111,793 |
|
| Investor relations |
|
|
771,073 |
|
|
|
6,663 |
|
| Share based compensation |
|
|
20,923,850 |
|
|
|
- |
|
| Other general and administrative expense |
|
|
728,514 |
|
|
|
466,084 |
|
| Interest expense - related parties’ loans |
|
|
357,672 |
|
|
|
2,559,456 |
|
| Loss on extinguishment of Bridge loan - related party |
|
|
- |
|
|
|
2,069,923 |
|
| Interest income |
|
|
(80,424 |
) |
|
|
- |
|
| Other Income |
|
|
(240,138 |
) |
|
|
- |
|
| Net loss |
|
$ |
(38,006,186 |
) |
|
$ |
(7,460,982 |
) |
| |
|
For the
Three Months Ended
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
| Revenues |
|
$ |
- |
|
|
$ |
20,000 |
|
| |
|
|
|
|
|
|
|
|
| Less: Significant and other segment expenses: |
|
|
|
|
|
|
|
|
| NEO100 |
|
|
109,166 |
|
|
|
98,399 |
|
| NEO100-02 |
|
|
93,326 |
|
|
|
96,367 |
|
| NEO212 |
|
|
279,074 |
|
|
|
197,962 |
|
| Pediatric |
|
|
50,178 |
|
|
|
1,591 |
|
| Laboratory |
|
|
107,465 |
|
|
|
- |
|
| Other |
|
|
38,123 |
|
|
|
165 |
|
| Total research and development expense |
|
|
677,332 |
|
|
|
394,484 |
|
| |
|
|
|
|
|
|
|
|
| Advisory fee |
|
|
- |
|
|
|
- |
|
| Legal and accounting |
|
|
520,364 |
|
|
|
590,984 |
|
| Employee Expenses |
|
|
163,887 |
|
|
|
- |
|
| Debt issuance and deferred offering costs amortization |
|
|
192,249 |
|
|
|
111,793 |
|
| Investor relations |
|
|
226,766 |
|
|
|
- |
|
| Share based compensation |
|
|
3,526,076 |
|
|
|
- |
|
| Other general and administrative expense |
|
|
593,609 |
|
|
|
205,860 |
|
| Interest expense - related parties’ loans |
|
|
48,750 |
|
|
|
1,171,963 |
|
| Interest income |
|
|
(28,725 |
) |
|
|
2,069,923 |
|
| Other Income |
|
|
(240,138 |
) |
|
|
- |
|
| Net loss |
|
$ |
(5,680,170 |
) |
|
$ |
(4,522,006 |
) |
|